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PROJECT DESCRIPTION(S) 
 
 
This Major Qualifying Project (MQP) was completed to satisfy the requirements of both 
the Biochemistry degree and the Professional Writing degree. The primary effort was to 
combine an authentic scientific research project conducted in the field of synthetic 
biology with concurrent analysis of written popular media on the subject. To complete 
this combined MQP, I conducted the scientific research portion in the Goddard Project 
Lab, under the advice of Professors Michael Buckholt and Natalie Farny, with the 
assistance of partner Andrew Baker. Simultaneously, I conducted the literature analysis 
portion independently under the guidance of Professor Brenton Faber. This exercise in 
science and communication was a meaningful study with the aim to understand both the 
technical and humanities disciplines within the context of each other.  
 
This full MQP report is a compilation of all of the work done for both majors. The first 
chapter contains the entirety of the literature analysis portion of the project in synthetic 
biology. The second chapter consists of the scientific research portion, performed in the 
laboratory. Finally, the report concludes with a reflection upon the overall experience, 
having immersed myself in both the technical and rhetorical aspects of a fascinating and 
influential new field: synthetic biology.  
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CHAPTER ONE 
 
 
Popularized Synthetic Biology: 
Public Perception & Understanding, 2006-2016 
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ABSTRACT 
 
 
Synthetic biology is a continuously emerging field of research and application that 
comprises engineering principles to further biology. This study explores the public 
understanding and perceptions of the science from 2006 to 2016, as represented by 
written popular media within that time, such as newspapers and magazines, both local 
and national. Though the idea of a synthetic biology originates from before the turn of 
the century, the field has emerged significantly in the last ten years. Synthetic biology 
follows similar patterns as other emergent sciences and technologies, as it strives to 
establish itself as a credible field at the forefront of science and society. However, contrary 
to other scientific areas such as nanotechnology, synthetic biology seeks to bridge existing 
areas together rather than offer itself as a unique and separately understood science. With 
applications ranging from medical care to biofuels, and concerns like bioterrorism and 
biosafety hazards, this study reveals the popular perceptions and understandings of 
synthetic biology over the last 10 years, and how this has shaped synthetic biology as a 
new, hybrid science in society. 
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INTRODUCTION 
Synthetic Biology: An Engineering  
Revolution in the Biological World 
 
 
Synthetic biology, more affectionately referred to as synbio, is a broad, interdisciplinary, 
ever-growing field that invokes engineering principles to devise new biological systems 
for adapting and creating life. The true definition still has not reached consensus among 
the scientific community, and its scope as an emerging science expands as related 
research accomplishes more in the name of synthetic biology.  
 
“Synthetic biology” as a recognizable term originated in 1910 with Stephane Leduc, a 
French scientist who desired his work to be considered as “synthetic” life forms (Tirard, 
2008). Following that time, however, both the term and the idea as a scientific discipline 
failed to catch on in more established scientific communities. The lack of necessary 
technology to substantiate and progress the field was a critical factor in its delayed 
significance. The contemporary understanding of synthetic biology, then, didn’t come 
into prominence until the 1970’s, when a notable geneticist by the name of Waclaw 
Szybalski described the “new era of synthetic biology” as one “where not only existing 
genes are described and analyzed but also new gene arrangements can be constructed 
and evaluated” (1978). This concept became more tangible once the century turned, when 
the first synthetic biological circuit was created in bacteria in the year 2000, with the work 
published in two separate Nature articles (Elowitz, 2000 and Gardner, 2000). The 
flowchart below conveys some of the major milestones and key players in the advent of 
synthetic biology following this first success story (Cameron, 2014; Mali, 2013; Purnick, 
2009; Specter, 2009; Zimmer, 2006). 
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Figure 1: Timeline of Major Synthetic Biology Milestones 
 
In the last few years to now, many of the earliest ideas of synthetic biology are becoming 
more capable of coming into fruition through advanced genome editing technology such 
as the CRISPR-Cas9 system, higher rates of industry-produced DNA, and the benefit of 
time, evidenced by increasing numbers of major publications in prestigious journals such 
as Cell, Nature, and JBC.  
 
The Public Appearances of Synthetic Biology 
In the last 10 years, as popular media reported on the field of synthetic biology, it 
associated the science with much of the same applications that the public associates other 
respected science fields with. Most often expressed as a means to medical advancements, 
improvements to the environment and agriculture, and a new source for fuel, synbio 
promises a wide variety of solutions to society’s most pressing and timeless needs. The 
field is dominated by the enduring frontier of genetic engineering and using genetics as 
a circuitry to life, with standards and parts to build custom systems. Contrary to such a 
clinical, systematic approach, the field also emphasizes a need for using bacteria as a life-
infused research tool. Accordingly, the media also reports synthetic biology as a science 
raising important questions of policy and supervision, if not expressing an urgent need 
for increased research regulation. 
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DATA COLLECTION & ANALYSIS 
 
 
For this study, to better understand the public understanding of the emerging field of 
synthetic biology and its potential acceptance within both scientific and nonscientific 
communities, I went to the written public media as a representation of synthetic biology’s 
public perceptions. I followed a method similar to the one outlined by Faber in his study 
on the emergence of nanoscience and nanotechnology (2006). To uncover a full spectrum 
of public perceptions, I used the expansive media database provided by my university, 
Worcester Polytechnic Institute (WPI). Through this connection, as well as through 
independent subscriptions, I was able to access newspaper and magazine articles from 
many sources. In order to represent as well as possible the entirety of public media in 
North America, I chose two major national sources: the Washington Post and New York 
Times, as well as eight regional publication sources from across the country: the Boston 
Globe, San Jose Mercury News, Chicago Tribune, Orlando Sentinel, Houston Chronicle, 
Seattle Times, Los Angeles Times, and The Day (New London). I determined my time 
period of the most recent ten years (January 1 of 2006 to December 31 of 2015) as a critical 
period in synthetic biology’s modern popular history, and an appropriate scope for this 
study. The keyword term remained “synthetic biology”, and I included in my search 
query only those articles that had their full text available online.  
 
The first search with these parameters generated a total of 563 articles. For a shallow 
understanding of the field and of the material I would be working with, I read the 
abstracts and/or skimmed through each of the articles. Through this process, I 
determined many articles to be repeats or not actually relevant to the field of synthetic 
biology. After manually reviewing each article, and eliminating all repeated or irrelevant 
articles, I established a final list of 162 articles on synthetic biology that I would then 
include in the data set for my study. The articles ranged from a few sentences long to 
sixteen pages. Interestingly, only six of the 162 articles contained the entire phrase 
“synthetic biology” in their headline titles. Figure 2 below depicts the number of articles 
about synthetic biology in each year of my chosen ten-year span: 
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Figure 2: Appearances of Synthetic Biology in Popular Articles from 2006-2016 
 
 
Understanding the Value of Synthetic Biology 
The next point of interest I had in the media’s portrayal of synthetic biology over the 
years was the value of the field: was this emerging scientific discipline regarded as 
positive in the public eye, negative, or perhaps both, or neutral? Furthermore, did the 
understanding in written media change significantly as the field grew in prominence in 
the public sphere? To gain insight into this, I read each article for its overall portrayal of 
synthetic biology and recorded the articles as positive, negative, neutral, or both (positive 
and negative).  
 
The Public Associations with Synbio 
While going through the process of reading each of the articles in my data set, I recorded 
the most prominent topics written about as associated to synthetic biology. From this list 
of 41 topics, I arranged 24 major categories that comprised of all of them. I refer to these 
24 major topic categories henceforth as representations. After creating this list, I then 
returned to each of the 162 articles in my data set to read them yet again and track which 
representations occurred in each article, to gain an idea of what synthetic biology is most 
associated with over time. 
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FINDINGS 
 
 
The Value of Synthetic Biology 
The first results generated from this study unveil the portrayal of synbio in written public 
media as positive, negative, neutral, or both. Figure 3 below shows the percentage of 
articles about synthetic biology with each indicated value, for each year:  
 
 
 
Figure 3: Depiction of Synbio Value – Positive, Negative, Both, and Neutral 
 
For simplification purposes, I then re-generated a graph that no longer includes articles 
that contain both a positive and negative idea of synthetic biology (“both”), or none at all 
(“neutral”). Following, Figure 4 shows articles that are more polarized as either 
overwhelmingly positive or negative: 
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Figure 4: Simplified Depiction of Polarized Synbio Articles – Positive or Negative 
 
There are a few interesting things to note in the portrayal of synthetic biology as positive 
or negative over time. The period between 2007 and 2009 contained no articles that were 
overtly negative, and the percentage of negative articles otherwise remains relatively 
stable between 10% and 20%, with the exception of the year 2013, which sees a spike of 
negative articles at just over 20%. The three years with the largest percentages of a 
positive portrayal are 2006, 2011, and 2014, with mainly positive articles consisting over 
40% of the data set in those years. Meanwhile, 2010 was the year with the least amount 
of articles portraying synthetic biology positively, with a meager 5%.  
 
Representation by Association 
The list of representations of synthetic biology stand for the major topics that the science is 
associated with, and these categories come directly from the text of the data set. 
Assuming equal occurrence, each of the 24 representations would in theory comprise of 
roughly 4% of each year’s total articles. However, as this study sought to find, the 
representations yielded great variability in their rate of occurrence. Regardless of the 
quantity of articles in each year, every year was dominated by one or more of the 
representations at 10% or higher of the total representations in that year. These major 
representations contribute to a common public understanding of synthetic biology in 
each of the last ten years. Figure 5 depicts which of the representations dominated 
through the written media of our data set in each year, providing insight into the major 
“buzzword(s)” of synthetic biology over time:  
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Figure 5: Table of Top Major Synbio Association by Year from 2006 to 2016 
 
Year Major Representation(s) with at least 10% 
2006 Genetic Engineering, Genetic Circuitry (Standards & Parts), and  
Industry & Funding/Investment 
2007 Biofuels/Energy Applications and 
Venter- Biography 
2008 Bacteria 
2009 Synthesizing Artificial Life 
2010 Venter- Biography 
2011 Bacteria and Competition 
2012 Medical Applications 
2013 Policy & Regulation (Biosafety) 
2014 Medical Applications 
2015 Medical Applications and  
Genetic Engineering 
 
This study desired to gain a more thorough, appreciable view of the understanding of 
synthetic biology in the public sphere. Therefore, it is crucial that I identified not only the 
representations with the highest occurrences, but the rate of occurrence for each 
representation. In this way, I could interpret the understanding and perceptions of synbio 
from how it is most often associated and least often associated, further altered by time.  
 
The 24 representations previously identified occurred a total of 764 times. On average, 
each representation appeared in 32 articles, and each article averaged 7 representations. 
The total number of representations found in each year is directly proportional to the 
number of articles about synthetic biology in each year. Figure 6 details those 7 
representations that had higher than average occurrences. Figure 9 details the 8 
representations that had the average amount of occurrences. Finally, Figure 12 details the 
9 representations that had less than average occurrences. Figures 7, 10, and 13 each show 
in a binary fashion the appearance of representations over the 10-year time span. The last 
charts in each section, Figures 8, 11, and 14 show the trends for each representation in 
each year, graphed to discover any remarkable occurrences.  
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Synthetic Biology: High-Occurring Representations 
 
Figure 6: Table of Topic Categories, High Count (>39) 
 
Topic Total 
Medical Applications 68 
Genetic Engineering 63 
Policy & Regulation (Biosafety) 57 
Bacteria 53 
Biofuels/Energy Applications 42 
Environmental/Agricultural Applications 40 
Genetic Circuitry (Standards & Parts) 40 
 
Figure 7: Presence of Topic Categories, High Count (>39), for each year 
 
TOPIC // YEAR 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ALL 
MEDICAL APPLICATIONS x x x x x x x x x x x 
GENETIC ENGINEERING x x x x x x x x x x x 
POLICY & REGULATION 
(BIOSAFETY) 
x x x x x x x x x x x 
BACTERIA x x x x x x x x x x x 
BIOFUELS/ENERGY 
APPLICATIONS 
x x x x x x x x x x x 
ENVIRONMENTAL/ 
AGRICULTURAL 
APPLICATIONS 
x x x x x x x x x x x 
GENETIC CIRCUITRY 
(STANDARDS & PARTS) 
x x x x x x x x x x x 
ALL x x x x x x x x x x x 
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Figure 8: Representations with High Occurrences Graphed by Year 
 
 
Temporal Findings 
Not surprisingly, each of the representations with higher-than-average rates of 
occurrence appear in each of the ten years from 2006-2015. Medical applications and 
genetic engineering are by far the representations that are most commonly associated 
with synthetic biology throughout time, with almost twice as many occurrences as 
average. Mostly, all of the high-occurring representations follow the overall trend(s) of 
synbio media. There are two notable exceptions, discussed briefly below. 
 
Biofuels/Energy Applications: This representation (marked in light blue in the graph 
above) directly contradicts the overall trend of appearance quantity of synthetic biology 
in written media. While the number of total articles about synbio from 2006-2015 is on a 
steady rise (with subtle increasing/decreasing trends within that time), the percentage of 
those articles representing synbio as having to do with biofuels & energy applications is 
on an overall steady decline over the course of those ten years. 
 
Genetic Circuitry (Standards & Parts): This representation (marked in very dark blue in 
the graph above) follows the three separate trend intervals as the overall article data (an 
increase from 2006-2008, brief increase from 2009-2010, and the largest increase from 
2011-2015). It differs, however, in that the percentage of genetic circuitry representations 
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continuously decreases over 10 years as the number of total articles about synbio 
increases- similar to the biofuels/energy applications representation overall trend. 
 
Synthetic Biology: Average-Occurring Representations 
 
Figure 9: Table of Topic Categories, Average Count (25-39) 
 
Topic Total 
Industry & Funding/Investment 38 
Venter- Biography 37 
GMO & Foods 36 
Morality (Bioethics) 35 
Synthesizing Artificial Life 32 
Competition 28 
Globalism 28 
Bioterrorism 27 
 
 
Figure 10: Presence of Topic Categories, Average Count (25-39), for each year 
 
TOPIC // YEAR 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ALL 
INDUSTRY & FUNDING/ 
INVESTMENT 
x x x x x x x x x x x 
VENTER- BIOGRAPHY x x x 
 
x x x x x x 
 
GMO & FOODS x 
 
x 
 
x x x x x x 
 
MORALITY (BIOETHICS) 
 
x x x x x x x x x 
 
SYNTHESIZING 
ARTIFICIAL LIFE 
 
x x x x x x x x 
  
COMPETITION x x x x x x x x x x x 
GLOBALISM x x x 
 
x x x x x x 
 
BIOTERRORISM x x x x x x 
 
x x x 
 
ALL 
  
x 
 
x x 
 
x x 
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Figure 11: Representations with Average Occurrences Graphed by Year 
 
 
Temporal Findings 
The years 2008, 2010, 2011, 2013, and 2014 each contain at least one occurrence of every 
one of the average-occurring representations. However, the only two average-occurring 
representations that occur in at least one article every year are Industry & 
Funding/Investment and Competition. Only about half of the average-occurring 
representations follow the same trend(s) as the total quantity of synbio articles does. 
 
Industry & Funding/Investment: This representation (marked in medium blue in the 
graph above) somewhat contradicts the overall trend of appearance quantity of synthetic 
biology in written media. The percentage of this representation actually decreases from 
2006 to 2009 while most representations increase, only to then follow the trend by 
increasing from 2011 to 2015.  
 
Venter- Biography: This representation (marked in red in the graph above) is noticeable 
for the significant spike in its percentage in the year 2010, when all other representations 
are significantly reduced compared to the other years. Furthermore, there is only a small, 
rather stable percentage of these representations from from 2011 to 2015, while the total 
number of representations/articles about synbio increases drastically. 
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Synthesizing Artificial Life: This representation (marked in light blue in the graph 
above) creates its own intriguing pattern. With the exception of none in 2006 and a 
reduced percentage in 2009, this representation contributes a high percentage from 2007-
2010, where it then drops to provide only a small, stable percentage of representations 
from 2011-2014 (and none in 2015). 
 
Competition: This representation (marked in yellow-orange in the graph above) follows 
a trend opposite to the overall article trend; barring 2006, it decreases over the 10 years 
while all others generally increase. 
 
Bioterrorism: This representation (marked in brown in the graph above) is dominated by 
a majority percentage of its representations being in 2006 to 2008, as well as 2010. Yet, 
these years are the ones characterized by the lowest overall articles on synbio. 
 
Synthetic Biology: Low-Occurring Representations 
 
Figure 12: Table of Topic Categories, Low Count (<25) 
 
Topic Total 
Church- Biography 24 
High-Throughput Methods 20 
Yeast 20 
Science Fiction/Fantasy 17 
Revolutionary/ "Cutting-edge" 16 
Other (miscellaneous) 14 
Software/Computer Applications 12 
Biomaterials Applications 9 
Keasling- Biography 8 
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Figure 13: Presence of Topic Categories, Low Count (<25), for each year 
 
TOPIC // YEAR 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ALL 
CHURCH- BIOGRAPHY 
 
x x x x x x x x x 
 
HIGH-THROUGHPUT 
METHODS 
x x x 
 
x x x x x x 
 
YEAST x x x 
 
x 
  
x x x 
 
SCIENCE FICTION/ 
FANTASY 
 
x x x x x x x x x 
 
REVOLUTIONARY/ 
"CUTTING-EDGE" 
x 
 
x 
 
x x 
 
x 
 
x 
 
OTHER 
       
x x x 
 
SOFTWARE/ COMPUTER 
APPLICATIONS 
x 
     
x x x x 
 
BIOMATERIALS 
APPLICATIONS 
x x x 
 
x 
  
x x x 
 
KEASLING- BIOGRAPHY x x x 
  
x 
 
x 
   
ALL 
       
x 
   
 
 
 
 
Figure 14: Representations with Low Occurrences Graphed by Year 
 
Temporal Findings 
Only the year 2013 contains each of the low-occurring representations. None of the low-
occurring representations persist throughout all of the years. In their limited 
appearances, these less enduring topics associated with synthetic biology follow similar 
patterns as the overall trend(s) of synthetic biology articles. Their adherence to the 
prescribed trend(s) is discussed at large in the following section (Discussion). 
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DISCUSSION 
The Dynamic Face of #Synbio 
 
 
There is little doubt that synthetic biology is in an exciting era of technological 
advancement, benefitting from a snowball effect of enthusiasm and support from a 
variety of stakeholders: students, teachers, researchers, the government, and industry. It 
is important to recognize, however, that in very recent years, there is a stable percentage 
of negative articles. Rather than overwhelmingly positive coverage as more information 
about synthetic biology and its applications are published, the public remains hesitant. It 
is only logical for the public to be skeptical when synbio first appears as a new science in 
media in 2006, and again logical that when there are not many articles about synbio in 
general, the concerns about the science are also diluted. The turning point that reveals 
the continued hesitancy is in 2010 when there is a large spike in total synbio-related 
articles, accompanied by a proportionally large spike in negative article portrayals. Even 
though the percentage of negative articles remains the same in 2011 as it was in 2010, the 
percentage of positive articles greatly increases, (in fact, taking the place of neutral 
articles). This seems to serve as a reinforcement of the durability of synthetic biology as 
an emerging field, despite all concerns. While this study is obviously limited by the 
current time, it would be incredibly beneficial and revealing to conduct a more 
longitudinal study to observe these value trends continued from 2016 onwards, as the 
field undergoes more growth and coverage.  
 
The ten-year span between 2006 and 2016 encompasses much of, but not all, of synthetic 
biology’s earliest years. This particular timeframe, though, is fitting as it was in 2006 that 
artemisinin (an antimalarial) became known as the first “marketable product” 
attributable to synthetic biology, and SynBERC (Synthetic Biology Engineering Research 
Center) was created: two major recognitions for a still-emerging field needing a foothold 
in society’s mind. Only the year 2013 contains every one of the 24 representations. This is 
despite the fact that 2013 is not the year with the highest amount of total articles or 
representations. This may mark 2013 as the year in which synthetic biology branches itself 
out, having enough foundational support and recognition to begin developing in new 
years. It will be fascinating to see if the 2013 invention of CRISPR-Cas9 gene editing 
technology will coincide with this allowance of synthetic biology to apply itself to even 
more of society’s needs and researcher’s curiosities.  
 
Some of the most surprising data arising from this study actually arises from several of 
the representations that occur less than average (low occurrences). Faber used 
nanoscience as his example emergent scientific discipline in a comparative media study, 
and in his results, “Science Fiction” was a high-occurring representation, whereas it is 
one of the lowest in this study. However, synthetic biology does appear to follow the 
trend in nanoscience to associate itself with science fiction/fantasy in the latter years of 
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its establishment- specifically, mostly from 2013-2015 (Faber, 2006). It appears that only 
once synthetic biology was presented in media with “known” science for the first half of 
its years did it venture into the more “unknown”, where more Other representations are 
seen in addition to Science Fiction/Fantasy, as well as Software/Computer Applications 
(not typically a topic combined with biology).  
 
Synthetic biology as newly formed scientific field is, therefore, following some of the 
same patterns and aligning with some of the same categories as other emerging scientific 
disciplines, in a general way. Much of the written media presents synbio in association 
with broad categories and what the science could mean for the advancement of public 
society, rather than explaining the hard science behind it. The claim to “cure cancer” and 
“invent a new sustainable biofuel” is not unprecedented, and furthermore unspecific. In 
particular, Medical Applications was also one of the highest-occurring representations of 
nanoscience as it struggled to emerge itself. This familiar scientific aim time and time 
again yields to both the public’s idea of scientific research as well as the much-needed 
conveyance of the scientific world to gain support and funding from the public- who 
would refute a science discipline that holds the key to unlocking disease, obesity, global 
warming, clean water, and food shortages? Alas, even with this common theme to 
emerging science, much of the same criticisms appear throughout the media as well. As 
a new, not-yet-understood science presents itself to the layman, making lavish claims and 
expressing itself as the magic to life, there is also the stream of concern and discussion of 
regulation. Another noticeable similarity in the process of the emerging science is the 
prominence of a scientific figure- while Drexler led the nanotech world, Craig Venter 
plays a gargantuan role not only in the research of synthetic biology but in the public 
representation of it.  
 
But, synthetic biology deviates from the pattern(s) of emerging science in at least one 
major way. Other fields such as nanoscience have attempted to substantiate themselves 
by proving that they are radically different, and wanting to establish their own 
programs/departments/labs dedicated to purely this new field of science, arguing that 
it will replace previous notions of physics or biology, and needing its own place in the 
scientific community. Synbio, on the other hand, is a true bridge between current 
understandings of engineering and biology, and instead of pressing for separate 
recognition, throughout the articles of this data set, it consistently announces itself as 
such. It capitalizes on the known area of genetic engineering and relies on this credibility 
to establish its own further aims and progresses. Instead of fearing the association with 
other existing sciences and technologies, it is grateful to the work that these disciplines 
have given for its own creation. Ultimately, perhaps this will prove to succeed in ways 
other disciplines haven’t, not only in the lab but in the public eye. 
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CONCLUSION 
Synthetic Biology as a Hybrid 
 
 
The nexus of synthetic biology in biology and engineering - life and machines - is a 
fascinating blend of two long-well-known sciences. The interplay between these two is 
the force that stabilizes and propels the emerging area of synbio, and the interface 
between lifeless and life-prone areas is perhaps what lends to synbio’s substantial current 
success. Only time will tell how the public continues to perceive and value the emergent 
discipline. For now, scientists will continue to tinker with DNA, repress genes, transplant 
bacterium genomes, reinvent species, alter foods- many of the old scientific ideas 
rebranded in a heightened way, under the new guise of synthetic biology.  
 
 
 
  
24 | P a g e  
 
 
 
 
 
CHAPTER TWO 
 
 
Single-Base Editing of Cellular  
mRNAby CRISPR/Cas9 
 
*Completed in partnership with Andrew Baker (BBT/CBC) 
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ABSTRACT 
 
 
Genetic engineering is currently dominated by CRISPR/Cas9 technology, promising 
precise multipurpose genome editing. The 2016 WPI iGEM team investigated the 
potential of adapting this technology to direct single-base editing of mRNA by linking 
deactivated Cas9 to the C-to-U RNA editor enzyme APOBEC1. We pursued the re-
cloning and characterization of the dCas9/APOBEC fusion to identify and eliminate 
problems related to expression and toxicity. Ultimately, this adapted CRISPR/Cas9 
system could provide an advantageous method of editing, particularly for therapeutics. 
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INTRODUCTION 
A Revolution in Synthetic Biology: The CRISPR Way 
 
 
The natural CRISPR/Cas9 system employs a bacterial adaptive immune response in 
which clustered regularly-interspaced short palindromic repeats (CRISPRs) are 
recognized by the nuclease Cas9 and cleaved for the purpose of editing the gene in an 
effort to ensure organism survival. This system has been specially adapted for the use of 
targeting virtually any position in the genome by guiding the Cas9 to recognize specific 
sites of double-stranded DNA (dsDNA), usually via engineered single-guideRNAs 
(sgRNAs) (Ran et al. 2013). A simple diagram of the mechanism of CRISPR/Cas9 
technology is below: 
 
 
Figure 15: A Diagram of CRISPR/Cas9 Editing Technology (Lewis 2015) 
 
Because of its natural derivation and high efficiency, the CRISPR/Cas9 system has 
quickly developed into a highly-regarded gene editing technology, through both 
recombination-based and single-base editing. In recombination-based editing, Cas9 cuts 
the dsDNA at a target locus, where the DNA is edited in the desired way (i.e. gene edits, 
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knockouts), and the cell undergoes either non-homologous end joining (NHEJ) or 
homology-directed repair (HDR), although typically NHEJ (Ran et al. 2013). In single-
base editing, the CRISPR/Cas9 system foregoes double-stranded DNA cleavage but 
retains editing power through an attached DNA-editing deaminase enzyme called 
APOBEC, which targets specific bases to be changed to a different nucleotide, such as a 
C→U substitution (Komor et al. 2016). 
  
While CRISPR technology has become a rather valuable tool in modern molecular 
biology, the current system is not without its issues, both technically and ethically. 
Biologically, Cas9’s ability to cut so efficiently at specific sequences on the genomic level 
is what makes it such a useful tool; however, sequences similar to the target sequence are 
often also cut, resulting in unpredictable and irreversible off-target effects (Harrison et al. 
2014). After the initial cut by Cas9, cells routinely use the NHEJ repair pathway to repair 
the genomic DNA. This repair mechanism is often inaccurate and leads to frequent 
insertions, deletions, and changes of nucleotides. These indel and single-point mutations 
are unpredictable and irreversible, with the potential to yield drastic, undesirable results 
(Harrison et al. 2014). Lastly, the extent of complex post-transcriptional modifications and 
splicing variation allows for a myriad of uncontrollable outcomes, due to the nature of 
editing primary genetic material. Our project was motivated partially due to these 
technical concerns, and partially due to the share of ethical and safety concerns that 
naturally come from genetic engineering. 
  
In response to these concerns, one adaptation to the current CRISPR/Cas9 gene-editing 
system has been to target RNA instead of DNA. It has been shown that CRISPR/Cas9 
can in fact be programmed to recognize single-stranded RNA (ssRNA) while avoiding 
the corresponding DNA sequences, and further cleave the targeted RNA in this manner 
(O’Connell et al. 2014). Furthermore, the CRISPR/Cas9 system has been demonstrated to 
be useful for live RNA tracking in vivo (Nelles et al. 2016). Finally, very recent progress 
by the Huang group has addressed the need to develop an mRNA-based CRISPR tool; 
their work validated the possibility of efficient targeting of cellular mRNA by an 
enzymatically dead Cas9, without affecting its corresponding DNA segments (2016). 
  
Therefore, understanding the technical and ethical issues presented by the common 
system of DNA-targeting CRISPR/Cas9, having studied the precedent of RNA targeting 
with CRISPR/Cas9, and inspired by the foundational work of the 2016 Worcester 
Polytechnic Institute (WPI) iGEM team in this field, we developed an adapted 
CRISPR/Cas9 system that also targets mRNA (WPI_Worcester, 2016). Another 
significant change from the current technology is that it utilizes the DNA/RNA editing 
enzyme APOBEC to cause specific single-base edits. 
  
28 | P a g e  
 
 
 
Figure 16: A Diagram of Targeted mRNA Editing by dCas9/APOBEC 
 
In this way, we can make very precise adjustments to the mRNA of a desired organism, 
regulating its related protein levels, without editing a single nucleotide of DNA. 
Additionally, the application of this tool would be a temporary therapy; in the case of any 
unforeseen error or mutation, the same regulation could be easily reversed by stopping 
the editing of mRNA. We propose that this mRNA/CRISPR/Cas9-APOBEC system can 
be used for the same research and therapeutic purposes as the original CRISPR gene-
editing technology, but with significantly reduced scientific and ethical risk, as well as 
increased accuracy. 
 
Our project continued the foundational work done by the 2016 WPI iGEM team in its 
efforts to develop this promising adapted CRISPR/Cas9 therapy. Herein, we describe our 
attempt to re-clone the dCas9/APOBEC construct. We also describe our conclusion of the 
project with transfection trials of several constructs into mammalian cells.  
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MATERIALS & METHODS 
 
 
Preparation of pcDNA3.1+ 
We transformed 2 uL pcDNA3.1+ template vector DNA (provided by the WPI 2016 iGEM 
team) into 50 uL chilled, thawed competent DH5α e. coli cells. They were then incubated 
on ice for 30 minutes, heat shocked at 42°C for 1 minute, and incubated back on ice for 5 
minutes. 200 uL of SOC media was added to each 52 uL cell/DNA mix for a brief 
outgrowth period. The SOC media contained the following ingredients and then was 
sterilized and filtered: 0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, and 20 mM Glucose. The cells in the media were put into a 
shaking incubator at 37°C for 2 hours, then plated (in various quantities) on LB plates 
(made with 1 mL Ampicillin at a concentration of 100 mg/mL). These sat overnight in a 
37°C incubator. Single colonies were picked for overnight cultures in 3 mL LB (w/Amp) 
each. These were mini-prepped using the Macherey-Nagel NucleoSpi Plasmid Mini Kit 
(Bethleme, PA) per the manufacturer’s instructions. The mini-prep products were run 
through a 1% agarose gel at room-temperature and 100 Volts, visualized by SYBR (from 
Qiagen), then cut out and gel-purified by Macherey-Nagel Gel and PCR Clean-Up Kit per 
the manufacturer’s instructions (Registry of Standard, n.d.). Verification gel(s) can be 
found in Figure 1 of Appendix B.  
 
Amplification of dCas9 and APOBEC 
dCas9: We amplified dCas9 DNA template (provided by the WPI 2016 iGEM team) via 
PCR reactions with Q5 master mix (New England BioLabs, Beverly, MA), using the 
following protocol:  
 
1x  [95 for 02:00] 
30x [95 for 00:30] 
 [59 for 00:45] 
 [72 for 04:30] 
1x  [72 for 10:00] 
Hold at 10 degrees for infinity 
 
The PCR product was run in a 1% agarose gel, visualized by SYBR (from Cambrex in 
Rockland, Maine), cut out and gel-purified by Qiagen purification kit. Verification gel(s) 
can be found in Appendix B. 
 
The temperature for annealing in the dCas9 amplification protocol was established by 
performing a gradient-temperature PCR reaction. We ran 12 identical reactions, each of 
15 uL, spanning from 45 to 62 degrees Celsius. The brightest bands when visualized in 
an agarose gel by SYBR allowed us to calculate the optimal annealing temperature to be 
59 degrees. For the gel results and calculation, please refer to Figure 2 of Appendix B. 
30 | P a g e  
 
APOBEC: We amplified APOBEC with 1Xten linker, 2Xten linker, and 3Xten linker 
(provided by the WPI 2016 iGEM team) via PCR reactions with Q5 master mix, using the 
following protocol: 
 
1x  [95 for 02:00] 
30x [95 for 00:30] 
 [55 for 00:45] 
 [72 for 01:00] 
1x  [72 for 10:00] 
 Hold at 10 degrees for infinity 
 
The PCR products were treated as described above. 
 
Cloning of dCas9 into pcDNA 
We used Gibson cloning method to attempt to clone dCas9 into our pcDNA3.1+ vector. 
We mixed 100 ng of gel-purified pcDNA3.1+ vector DNA with 200 ng of gel-purified 
dCas9 insert DNA, along 10 uL of NEBuilder HiFi DNA Assembly Master Mix and the 
remaining amount needed of deionized water to create a 20 uL total reaction. The 
reactions were incubated in a PCR machine for 30 minutes at 50°C. The reaction product 
was then transformed by mixing 2 uL of the product into 50 uL of thawed competent 
DH5α e. coli cells (obtained by Professor Farny’s competent cell stock in the -80 degrees 
Celsius freezer), incubated on ice for 30 minutes, heat shocked at 42°C for 30 seconds, and 
put back on ice for 2 minutes. 950 uL of room temperature SOC media was added, the 
mix was then incubated at 37°C with vigorous shaking for 1 hour, then plated on 
prewarmed LB (w/Amp) plates, and incubated overnight at 37°C (Gibson, 2009 and New 
England BioLabs, n.d.). We further attempted to repeat this with un-gel-purified dCas9 
insert DNA, all the rest remaining the same. Our control for these reactions was to plate 
the plasmid without insert DNA, and cells without any transformation plasmid or insert 
DNA (Registry of Standard, n.d.). 
 
Transfection of dCas9/APOBEC Constructs 
For transfection, we followed the protocol found with TransFectin (from Bio-Rad), a 
highly efficient, lipid-based transfection reagent. We plated 600,000 cells into the wells of 
a 6-well plate and allowed 24 hours for adherence. We then added 2 µg of DNA with 10 
µL TransFectin and counted this as time = 0 hours for imaging by microscopy. We 
performed two transfections using this basic process. 
 
The first transfection was conducted with H1299 cells, which is a human non-small cell 
lung carcinoma cell line, and was done as described above. The DNA inserted into the 
cells were the following constructs: APOBEC 1X, APOBEC 2X, APOBEC 3X, BE2, dCas9, 
and pRETRO. The control was cells with no DNA. The cells were incubated at a stable 37 
degrees Celsius. After 48 hours, the cells were imaged (please see Results section).  
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The second transfection was conducted with MCF7 cells, a breast cancer cell line, and was 
done as described above, with the following exception: the cells were incubated for 4 
hours before changing media, completely removing the transfection reagent. The media 
used was standard DMEM, 10% FBS and 1% Pen-Strep (Gibco). The following three 
variations were the conditions used: transfection reagent and DNA, DNA only, and 
transfection reagent only. The DNA added for this transfection was the BE2 construct 
(Addgene Plasmid #73020). The control well contained only cells. All cells were imaged 
at 24 hours (please see Results section).   
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RESULTS 
 
 
The first part of our project consisted of the re-cloning of dCas9 into the pcDNA3.1+ 
vector, to be followed by APOBEC with the 1X, 2X, and 3X size linkers. We first amplified 
our dCas9 DNA through multiple PCR reactions, but rarely were able to produce enough 
DNA to begin molecular cloning. Because of this issue, we optimized the PCR protocol 
by performing a gradient-temperature PCR reaction in which the annealing temperature 
of the reaction was increased incrementally. Below, Figure 17 illustrates the results 
collected. 
 
 
 
Figure 17: Gradient-Temperature PCR Gel Results 
 
The lanes in the two gels sequentially represent reactions 1-12 of the temperature 
gradient, ranging from 45 to 62 degrees. The results shown in Figure 1 suggest an optimal 
annealing temperature between 57.78 (reaction 9) and 59.2 (reaction 10) degrees. Based 
on these results, the annealing temperature used in future PCRs was set to 59 degrees 
(full calculation can be found in Figure 2 of Appendix B). Using this modified PCR 
protocol, we continued amplifying the dCas9 DNA and began attempting to clone the 
DNA into pcDNA 3.1+ via Gibson assembly. 
 
Inserting the dCas9 DNA into the pcDNA 3.1+ vector proved difficult for unknown 
reasons. We believe that because of dCas9’s size (approximately 4.2 kb), the DNA was 
simply too big to successfully integrate into the pcDNA 3.1+ plasmid in one step. We 
suggest that in the future, the dCas9 gene could be split into two or three parts, amplified 
separately via PCR and inserted individually into the plasmid. By splitting the gene into 
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parts, the size of the insert is dramatically reduced - possible making the cloning more 
successful.  
 
Because we had little time left in our MQP to complete the cloning process and transfect 
with our own constructs, we had the fortune to use iGEM’s previously made/purchased 
constructs for investigating transfection/expression of dCas9 and APOBEC in 
mammalian cells. We began by first taking each individual component of the pRETRO 
iGEM-constructs, as well as the AddGene plasmid BE2, and transfecting H1299 
mammalian cells. Figure 18 below clarifies each of the DNA constructs we added to our 
transfection(s): 
 
Figure 18: Table of DNA Constructs Used in Transfection(s) 
 
DNA Construct Plasmid Backbone Contents Source 
“pRETRO” pRETRO none AddGene 
“dCas9” pRETRO dCas9 iGEM 
“APOBEC 1X” pRETRO APOBEC 1X iGEM 
“APOBEC 2X” pRETRO APOBEC 2X iGEM 
“APOBEC 3X” pRETRO APOBEC 3X iGEM 
“BE2” pCMV dCas9/APOBEC AddGene 
 
 
Following, Figure 19 shows the images taken from the first transfection, which was done 
with H1299 cells: 
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Figure 19: Cells 48 Hours Post-Transfection with Various Constructs Compared to Control 
 
 
From this transfection, we realized the incidence of massive cell death in every well 
except for the one that contained only cells (no transfection reagent and no DNA) - 
specifically, after 48 hours, the cells with DNA added became suspended in the media, 
over 80% dead as compared to the anchored, 90% alive “cells only” well. This was an 
unexpected result, especially because a simple vector such as pRETRO should not 
theoretically cause cell death. Therefore, we wanted to determine which of the two added 
transfection ingredients (reagent or DNA) was the one responsible for killing the cells. To 
do this, we conducted a second experiment including proper controls to make a more 
thorough and substantiated conclusion. This second transfection involved transfecting 
MCF7 mammalian cells with only BE2. We decided to switch to the new cell type, MCF7, 
to determine if the cell type played any role in the results, and to prevent cell death if 
caused easily to the previous cell types tried (293T’s and H1299’s). 
 
Following, Figure 20 shows the images taken from the second transfection, which was 
done with MCF7 cells: 
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Figure 20: Cells 0 and 24 Hours Post-Transfection, Testing for Toxicity Cause 
  
The images collected above indicate that the transfection reagent used (TransFectin) is 
responsible for the quantified cell death observed in both Figures 19 and 20. This result 
could be due to a variety of reasons including: the age of the TransFectin (4+ years), or 
the plasmid itself. While the second column in Figure 20 indicates that the DNA is not 
killing the cells, the DNA is not able to enter the cells because of the absence of 
TransFectin, thus it would be useful to recapitulate these results with a Transfectin-only 
culture. This is important to note because once TransFectin is added, the DNA forms 
complexes with the TransFectin and enters the cells. BE2 contains pRETRO as its plasmid 
backbone - a DNA sequence that originates from viruses. We suggest that cell death may 
be occurring in Figures 19 and 20 because of the use of pRETRO. As the DNA enters the 
cell, it may be integrating into the host genome and inducing apoptosis through either 
integrating in a non-optimal location (disrupting essential genes), or leading to interferon 
production in the cell which then leads to cellular apoptosis. We also recommend 
attempting the same transfections as above in media that does not contain antibiotic. 
While bacterial antibiotic, like Penn Strep, should not usually cause mammalian cell 
death, the increase in cell permeability via lipid-based transfection may be contributing 
to the observed cell death. Similarly, it is recommended that alternative transfection 
protocols be attempted. All of our recommendations are discussed in the following 
section. 
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DISCUSSION 
 
 
The foundational work completed by the iGEM team led to an exciting prospect for our 
MQP. It is indisputable that CRISPR technology offers boundless potential for 
applications ranging from medical to environmental. However, its technical concerns 
simultaneously present ethical concerns for the scientific community and the society at 
large. Firstly, accidental release of any genetically modified organism could lead to severe 
ecological disruptions. Any experimental organisms released into an ecosystem could 
quickly proliferate, spreading possibly hazardous DNA sequences throughout the 
ecosystem (Rodriguez 2016). A second, more economical concern, is the recent practice 
of patenting DNA sequences. CRISPR technology is frequently used to create and insert 
laboratory-produced DNA sequences that are then often used in applications for patents. 
This creates the ethical concern of whether it is morally right to patent genes or other 
DNA sequences (Rodriguez 2016). A final and most severe ethical concern associated 
with CRISPR is the practice of editing human genomes. Already, UNESCO has issued the 
Universal Declaration on the Human Genome and Human Rights which recommends a 
moratorium on human germline genome editing. Despite similar recommendations to 
avoid using tools like CRISPR on the human genome, some have argued the potential to 
treat a wide range of diseases, such as cystic fibrosis or sickle cell disease, through the 
tool (Rodriguez 2016). It is these concerns that have placed CRISPR into a negative light 
in terms of public opinion and have founded the need for a safer, less controversial 
alternative to CRISPR. 
 
While we encountered obstacles in the lab that prevented us from progressing further in 
the development of this adapted CRISPR/Cas9 technology, we enjoyed the experience 
immensely and learned boundless skills in troubleshooting and critical thinking. We 
stress the importance of further developing this adapted CRISPR technology and highly 
encourage a future MQP team to pick up where we left off. To this end, we have compiled 
a list of major routes that we suggest such a team to proceed on. We look forward to the 
future development of this project. 
 
Our first major suggestion is the continued cloning of dCas9/APOBEC into the 
pcDNA3.1+ vector. Future persistence in these cloning aims should include APOBEC 
inserts of various size linkers into pcDNA3.1+, as well as into other standard and atypical 
vectors. Given the trouble we faced with cloning in dCas9, we propose splitting the dCas9 
DNA into multiple parts and cloning them into the vector in pieces. Reducing the 
substantial size of the insert when cloning the DNA may facilitate uptake of the gene into 
a plasmid. 
 
Our second major suggestion is determining successful alternate transfection protocols 
to reduce toxicity to the cells. We suggest attempting the same transfection as done above, 
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but in media that does not contain any antibiotic (our attempt at this yielded large 
contamination, making the cells difficult to image- we suggest trying several 
concentrations/quantities of antibiotic). We also suggest transfecting the cells using 
plasmids that do not originate from viruses in order to reduce possible interferon 
production post-transfection. Finally, we also suggest finding alternate methods of 
transfecting the DNA into the cells, in order to accurately determine the effect of the 
dCas9 construct(s), such as a calcium phosphate method. 
 
Once the dCas9/APOBEC construct(s) have successfully been cloned into an appropriate 
plasmid vector and the construct(s) have been transfected into mammalian cells, the next 
major step in the project can be continued. Firstly, one would need to verify the 
expression of the construct in vivo. Following that is to proceed with introducing guide 
RNA to target the CRISPR/Cas9 system for editing. Finally, conduction of RNA 
collection and sequencing, as well as protein analysis, would both be done to test for 
successful mRNA editing.   
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CHAPTER THREE 
 
 
A Reflection on the Socio-Technical Paradigm 
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A Personal Reflection on the Socio-technical MQP Experience 
 
 
“This doesn’t belong here.”  
 
These are the words I continue to remember the most from Project Presentation Day on 
April 20, 2017. I was presenting my MQP at the CBC/BBT poster session in the Campus 
Center Odeum. This included a poster with my partner representing our work in the 
laboratory in the area of synthetic biology, on developing an adapted CRISPR/Cas9 
technology for genetic engineering, accompanied by a poster representing my individual 
work on popularized synthetic biology in media. I had set the posters up, side-by-side, 
as I had been designated to do, and was excited to share my experience with the many 
students, faculty, and family that would be attending the events of the day.  
 
The students of the CBC/BBT departments were instructed to prop up our posters and 
then attend a lecture in the room next door before the poster session would begin. My 
peers did this, and I followed suit. However, before the speaker officially began, I realized 
I had forgotten something back at my posters, so I walked quickly over to where my 
backpack was lying near them. There stood a professor having a conversation with 
another faculty member, and that’s when I heard the words:  
 
“This doesn’t belong here”. 
 
They had not realized I was there, or at least that it was my posters they were talking 
about. It was obvious that the CBC/BBT professor was referring to my Professional 
Writing poster on synthetic biology, as she peered at it, scrutinizing. The tone of the 
words, said so casually, hit me in a profound way. At first, I couldn’t help but be hurt. 
“My work doesn’t belong here?”, I thought to myself questioningly in a broken-hearted 
way. I didn’t have much time to ponder it further, as I hurried back to claim my seat at 
the morning lecture. But, as the speaker continued on to the better half of an hour, my 
mind began to drift away from the antibiotic resistance content she was explaining so 
intelligently, and back to the claim I had heard just a while ago in the adjacent room.  
 
“This doesn’t belong here”.  
 
On one hand, I took it personally. I fervently believe I deserved to present my combined 
MQP work at the CBC/BBT session. Even if one of my two posters was Professional 
Writing-focused, it was relevant to my work in the lab, relevant to the scientific 
community at WPI. I had not replaced my work in the lab with a silly composition on the 
subject- I was not trying pompously to earn the same credit with a lesser project. Rather, 
the PW poster was an addendum to my work in the lab, a sister study. Of course, I am 
biased to the importance of my own research. But, as I mulled over those same words, 
ringing over and over again in my head, I also realized the inherent bias as demonstrated 
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by the CBC/BBT professor’s casual phrase. In one striking moment, I couldn’t help but 
suddenly think how perfect those words really were in embodying the entirety of my 
project. After all, it’s true- as science and humanities currently stand, my project didn’t 
belong there. Given their way, the scientific community would not want “my 
humanities” taking up “their space”. Here, I don’t talk pointedly anymore about just the 
one CBC/BBT professor and the departments at WPI, but rather the general academic 
and practical disciplines of the “sciences” and the “humanities”. In that moment, I no 
longer took the words personally, but genuinely smiled at the magic in the meaning they 
held, relishing them as the exact, most perfect embodiment of a reason for my project in 
the first place. This revolutionary moment in my mind fueled my fire to share my entire 
MQP experience throughout the day that followed.  
 
When I began my combined MQP, I really had no idea what I had signed up for. I set my 
synthetic biology project up with my CBC/BBT advisors first because it was easier to do 
so and it required more advanced planning. I confirmed with them the capability to 
combine lab work with an extra writing aspect guided by an additional advisor. Then I 
found my PW advisor and we tossed ideas at each other through scattered emails while 
I was on IQP and over the summer, in regards to what avenues I could explore at the 
interface between research in a scientific discipline like synthetic biology and scientific 
communication. At the start of senior year, I was excited to dive into the MQP headfirst. 
Having prior experience with CRISPR in the lab, I felt fortunate to be given the 
opportunity to continue in this topic as one of the synthetic biology teams in the project 
lab. Narrowing down my focus for the writing side was not as easy of a task – there are 
too many fascinating avenues to explore in scientific communication and rhetoric. Once 
I read a prior study conducted by my advisor on popularized nanotechnology, however, 
I felt passionate about doing a similar project for the emerging field of synthetic biology.  
 
As a primarily Biochemistry major knee-deep in scientific material, my perspective on 
scientific articles in popular media is at a stark contrast to how the audience outside of 
the scientific community views them. My interest lies in the understanding of synbio by 
the everyday readership of popular general magazines, like the New York Times and 
Boston Post. How do journalists portray the science, and in return, how do the readers 
perceive it? How in sync are these portrayals with the hard science being done in the lab, 
with the aims and achievements that scientists are actually striving for and 
accomplishing? Which community, the sciences or the humanities, is given the 
responsibility of determining this disconnect, if any, and how it should be remedied? 
Regardless of the accuracy of media coverage, scientists must address the public in their 
concerns and misunderstandings. Yet, as long as the science is propelled with promise to 
further the good of humankind, its investment is secured, and the two communities 
remain largely separated and in conflict with each other. 
 
It seems that these very separate circles of intelligent communities worry about the harm 
of each other before it happens, or point blame after harm occurs, but cannot seem to find 
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an adequate way of addressing harm in the moment. When humanities professionals, 
such as sociologists and philosophers, raise questions of concern in ethics and safety, for 
example, the morality of “playing God to synthesize artificial life”, the biohazard of 
releasing genetically modified organisms, or the fear of terrorist attacks by designer 
viruses, science is not halted- and nor should it be, as science plays a critical role in 
everyday society. Instead, politicians and other social agents react in one of two ways: (1) 
desiring to put regulations in place to prevent overstepping the bounds of “proper science” 
or (2) chastising a scientific act as having already stepped over those bounds. This description 
of ineffective pre-interruption or post-interruption is clinically explored in Paul 
Rabinow’s experience with SynBERC, outlined in his book “Designing Human Practices: 
An Experiment with Synthetic Biology”. Consistently, policies and regulations on 
scientific practice, as set primarily by humanities communities, are deemed outdated, 
extreme, or invalid for another reason. Similarly, scientific advances are often accepted 
with immense hesitation or outright refuted in humanities communities. In other words, 
there have either been little to no attempts at using the two disciplines together other than 
imposing one over the other, no attempts at bridging the two communities together to 
establish common goals and laws that can be agreed upon and followed by both- either 
this or all large-scale attempts thus far have proven unsuccessful. 
 
My limited socio-technical experience, working in both areas within the context of 
synthetic biology- conducting biology research and studying its social implications, has 
taught me very little and a great deal about this problem and its potential solutions at the 
same time. I have learned that there is no easy or immediate answer, at least not in present 
society, to the disconnect between the disciplines. Simply, the humanities does not 
understand science, just as science does not understand humanities, and the lack of 
understanding lends itself all too easily to impatience and under-appreciation. When the 
professor spoke the words that my PW poster did not belong in the CBC/BBT sphere of 
work, she said this not out of malice but out of an ingrained ideal of separation between 
the two departments. It is this barrier that prevents successful complementarity and 
integration between them that would prevent future tension.  
 
To the professor I overheard by chance, my PW poster was regarded as an irrelevant 
piece of work without taking the time to stop and look for what it really was. Moreover, 
it was disregarded as “just a project in the humanities”, without acknowledging its very 
tangible relation to synthetic biology and what value it had in telling scientists how the 
emerging discipline has established itself in the  mind of everyday readers, the ones who 
would be contributing to the funding and societal acceptance of the very same science 
researchers are trying to promote in society. My goal in completing this MQP was to do 
what little I could to broaden the minds of individuals in both academic communities to 
the importance of each other. I could not have learned what I did had I only kept my head 
down in the laboratory performing genetic engineering, and I could not have learned 
what I did had I only read popularized articles on synthetic biology. I wholeheartedly 
admit that because of my work across disciplines, I may have lost short-term efficiency 
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in the progress of either project, but it is truly fact that I am better served for the future 
by having done them together in one cohesive MQP experience.   
 
Through this MQP, I have embarked upon a personal journey in the socio-technical 
paradigm. As I venture on to a career combining both, learning and living the potential 
of a sociotechnical perspective, I know that regardless of what framework I’m presenting 
in, whether this be one of the humanities or of science, and regardless of the allowance 
or acceptance of any poster, I’ll always need to remember the importance of this broader 
perspective. As an aspiring scientist and communicator, I hope my MQP shows the 
incredible power of an exercise in both. We are all “layman” to what is outside of our 
fields, but it is our decision to remain captive by our bias or to find the value in what lies 
outside. It was my decision to pursue both a technical and a rhetorical degree, and 
because of this, truly combining my expertise in the two in this final MQP, that I feel 
prepared to look beyond the barriers of one discipline, and to always strive for the 
successful integration of both social and technical for the betterment of society as a whole. 
It is because of this decision, that even as a layman, my work will always “belong”. 
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APPENDIX A. 
Supplemental to CHAPTER ONE 
 
Figure 1: Table of Articles by Source and Year 
 
PUBLICATION/YEAR 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 TOTAL 
(1) Boston Globe 4 0 4 2 3 2 4 7 1 3 30 
(2) Chicago Tribune 0 0 0 0 0 0 0 0 2 1 3 
(3) Houston Chronicle 0 1 0 0 0 0 1 2 3 2 9 
(4) Los Angeles Times 1 0 0 0 0 0 0 1 5 8 15 
(5) New York Times 1 3 2 0 11 3 4 6 5 10 45 
(6) Orlando Sentinel 0 0 0 0 0 0 0 0 2 2 4 
(7) San Jose Mercury News 0 2 3 0 0 0 0 2 0 1 8 
(8) Seattle Times 0 2 2 1 2 1 0 3 0 1 12 
(9) The Day 0 1 2 0 0 0 1 0 1 0 5 
(10) Washington Post 1 2 1 1 3 0 4 3 5 11 31 
TOTAL 7 11 14 4 19 6 14 24 24 39 162 
 National Total 2 5 3 1 14 3 8 9 10 21 76 
Local Total 5 6 11 3 5 3 6 15 14 18 86 
 
 
Figure 2: Graph of Media Source, National vs. Regional, by Year  
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Figure 3: Value Tracking by Article 
 
ARTICLE 
CODE 
VALUE 
CLASS 
ARTICLE 
CODE 
VALUE 
CLASS 
ARTICLE 
CODE 
VALUE 
CLASS 
ARTICLE 
CODE 
VALUE 
CLASS 
 1_2006_1 Positive 3_2015_1 Negative _4 Both _2 Neutral 
_2 Positive _2 Positive 5_2013_1 Positive 8_2011_1 Positive 
_3 Both 4_2006_1 Positive _2 Positive 8_2013_1 Negative 
_4 Neutral 4_2013_1 Both _3 Negative _2 Negative 
1_2008_1 Neutral 4_2014_1 Negative _4 Both _3 Both 
_2 Both _2 Neutral _5 Both 8_2015_1 Positive 
_3 Both _3 Positive _6 Both 9_2007_1 Neutral 
_4 Positive _4 Neutral 5_2014_1 Neutral 9_2008_1 Neutral 
1_2009_1 Positive _5 Neutral _2 Positive _2 Both 
_2 Neutral 4_2015_1 Both _3 Both 9_2012_1 Negative 
1_2010_1 Neutral _2 Positive _4 Positive 9_2014_1 Positive 
_2 Both _3 Positive _5 Positive 10_2006_1 Negative 
_3 Negative _4 Neutral 5_2015_1 Neutral 10_2007_1 Neutral 
1_2011_1 Positive _5 Positive _2 Both _2 Both 
_2 Positive _6 Both _3 Both 10_2008_1 Neutral 
1_2012_1 Positive _7 Both _4 Both 10_2009_1 Both 
_2 Neutral _8 Both _5 Neutral 10_2010_1 Both 
_3 Neutral 5_2006_1 Both _6 Neutral _2 Neutral 
_4 Neutral 5_2007_1 Positive _7 Negative _3 Negative 
1_2013_1 Both _2 Positive _8 Both 10_2012_1 Negative 
_2 Positive _3 Both _9 Positive _2 Neutral 
_3 Neutral 5_2008_1 Both _10 Both _3 Neutral 
_4 Both _2 Neutral 6_2014_1 Neutral _4 Positive 
_5 Positive 5_2010_1 Positive _2 Positive 10_2013_1 Positive 
_6 Positive _2 Neutral 6_2015_1 Positive _2 Negative 
_7 Neutral _3 Neutral _2 Both _3 Both 
1_2014_1 Positive _4 Negative 7_2007_1 Positive 10_2014_1 Positive 
1_2015_1 Both _5 Neutral _2 Positive _2 Positive 
_2 Positive _6 Both 7_2008_1 Both _3 Both 
_3 Positive _7 Neutral _2 Positive _4 Positive 
2_2014_1 Neutral _8 Neutral _3 Both _5 Positive 
_2 Positive _9 Both 7_2013_1 Positive 10_2015_1 Neutral 
2_2015_1 Positive _10 Neutral _2 Negative _2 Negative 
3_2007_1 Neutral _11 Both 7_2015_1 Positive _3 Positive 
3_2012_1 Neutral 5_2011_1 Neutral 8_2007_1 Neutral _4 Both 
3_2013_1 Neutral _2 Neutral _2 Both _5 Neutral 
_2 Neutral _3 Negative 8_2008_1 Neutral _6 Negative 
3_2014_1 Negative 5_2012_1 Both _2 Both _7 Positive 
_2 Positive _2 Both 8_2009_1 Both _8 Both 
_3 Positive _3 Neutral 8_2010_1 Both _9 Both 
      _10 Both 
      _11 Negative 
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Figure 4: Graph of Synthetic Biology Value by Year 
 
 
 
 
Figure 5: Full List of Representation Categories  
 
Numerical Tracking 
Designation 
Representation Topic 
Articles with 
Representation Occurrence 
1 Bacteria 53 
2 Biofuels/ Energy Applications 42 
3 Biomaterials Applications 9 
4 Bioterrorism 27 
5 Church- Biography 24 
6 Competition 28 
7 Environment/ Agricultural Applications 40 
8 GMO & Foods 36 
9 Genetic Circuitry (Standard & Parts) 40 
10 Genetic Engineering 63 
11 Globalism 28 
12 High-Throughput Methods 20 
13 Industry & Funding/ Investment 38 
14 Keasling- Biography 8 
15 Medical Applications 68 
16 Morality (Bioethics) 35 
17 Policy & Regulation (Biosafety) 57 
18 Revolutionary/ “Cutting-Edge” 16 
19 Science Fiction/ Fantasy 17 
20 Software/ Computer Applications 12 
21 Synthesizing Artificial Life 32 
22 Venter- Biography 37 
23 Yeast 20 
24 Other 14 
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Figure 6: Representation Tracking by Article, for Representations 1-12 
 
  Representation Tracking 
 Code 1 2 3 4 5 6 7 8 9 10 11 12 
A
rt
ic
le
 T
ra
ck
in
g
 
1_2006_1 1 1    1      1 
_2       1   1   
_3 1     1 1 1 1 1 1  
_4         1   1 
1_2008_1 1 1       1    
_2 1 1  1   1  1 1  1 
_3 1 1  1  1  1 1    
_4       1  1 1   
1_2009_1     1        
_2             
1_2010_1      1   1    
_2 1   1         
_3    1       1  
1_2011_1 1     1 1      
_2 1 1   1 1 1 1 1   1 
1_2012_1  1    1 1   1  1 
_2             
_3  1    1 1     1 
_4             
1_2013_1    1         
_2     1        
_3             
_4     1    1 1 1  
_5            1 
_6            1 
_7             
1_2014_1 1         1   
1_2015_1 1 1   1  1 1     
_2       1     1 
_3             
2_2014_1             
_2 1            
2_2015_1        1  1   
3_2007_1 1    1 1    1   
3_2012_1         1    
3_2013_1             
_2  1           
3_2014_1        1  1   
_2          1   
_3  1     1  1   1 
3_2015_1          1   
_2             
4_2006_1   1       1   
4_2013_1    1      1 1  
4_2014_1        1  1   
_2             
_3 1            
_4             
_5         1    
4_2015_1 1    1  1   1   
_2       1   1   
_3  1     1 1     
_4             
_5 1            
49 | P a g e  
 
  Representation Tracking 
 Code 1 2 3 4 5 6 7 8 9 10 11 12 
A
rt
ic
le
 T
ra
ck
in
g
 
_6 1        1    
_7           1  
_8          1   
5_2006_1 1      1  1 1   
5_2007_1  1        1   
_2 1 1   1 1   1  1  
_3  1  1     1 1 1  
5_2008_1 1   1 1 1    1   
_2         1 1   
5_2010_1 1 1 1 1  1   1 1 1  
_2             
_3 1 1   1 1    1   
_4 1          1  
_5         1    
_6 1            
_7 1          1  
_8     1    1   1 
_9  1        1 1  
_10  1    1    1   
_11  1       1 1   
5_2011_1 1    1 1       
_2     1        
_3    1         
5_2012_1  1      1    1 
_2  1    1 1 1     
_3 1            
_4        1     
5_2013_1             
_2 1         1   
_3        1     
_4        1  1   
_5           1  
_6        1   1  
5_2014_1     1  1      
_2 1       1     
_3 1            
_4        1     
_5       1 1  1   
5_2015_1 1    1   1  1   
_2          1   
_3        1  1   
_4       1 1  1   
_5         1    
_6          1   
_7        1  1   
_8        1  1   
_9     1       1 
_10     1  1   1   
6_2014_1             
_2 1            
6_2015_1 1            
_2 1        1    
7_2007_1  1     1      
_2  1           
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  Representation Tracking 
 Code 1 2 3 4 5 6 7 8 9 10 11 12 
A
rt
ic
le
 T
ra
ck
in
g
 
7_2008_1 1 1  1     1  1  
_2  1         1  
_3 1 1 1 1   1  1 1   
7_2013_1       1  1    
_2       1 1     
7_2015_1 1        1 1   
8_2007_1 1 1  1 1 1    1   
_2 1 1  1     1   1 
8_2008_1 1 1  1 1 1       
_2 1 1  1  1  1 1    
8_2009_1 1   1  1   1 1   
8_2010_1 1        1 1   
_2          1 1  
8_2011_1 1 1    1  1  1 1  
8_2013_1        1  1   
_2       1 1  1   
_3  1 1    1 1 1    
8_2015_1            1 
9_2007_1 1   1     1    
9_2008_1    1         
_2 1 1        1   
9_2012_1             
9_2014_1   1   1 1   1   
10_2006_1    1     1  1  
10_2007_1 1 1   1 1       
_2  1 1 1  1 1  1 1  1 
10_2008_1 1    1 1       
10_2009_1  1  1  1 1  1 1   
10_2010_1 1 1  1   1 1  1   
_2             
_3 1 1 1 1   1      
10_2012_1  1     1   1   
_2     1       1 
_3       1   1 1  
_4         1    
10_2013_1      1       
_2       1 1   1 1 
_3  1     1 1 1 1 1 1 
10_2014_1             
_2       1 1  1 1 1 
_3    1         
_4           1  
_5 1  1    1      
10_2015_1           1  
_2 1       1     
_3 1       1 1 1   
_4          1   
_5             
_6    1      1   
_7 1  1   1 1  1 1 1  
_8  1  1   1      
_9     1     1 1  
_10        1   1  
_11  1   1  1 1  1 1  
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Figure 7: Representation Tracking by Article, for Representations 13-24 
 
  Representation Tracking 
 Code 13 14 15 16 17 18 19 20 21 22 23 24 ALL 
A
rt
ic
le
 T
ra
ck
in
g
 
1_2006_1 1  1          6 
_2 1            3 
_3      1  1   1  10 
_4 1            3 
1_2008_1   1      1 1   6 
_2  1 1  1    1 1 1  13 
_3   1  1        8 
_4 1  1          5 
1_2009_1         1    2 
_2 1            1 
1_2010_1   1          3 
_2     1 1   1 1   6 
_3     1     1   4 
1_2011_1 1            4 
_2      1   1    10 
1_2012_1 1  1          7 
_2    1    1 1    3 
_3 1            5 
_4 1            1 
1_2013_1    1 1        3 
_2   1   1 1      4 
_3 1            1 
_4   1 1  1       7 
_5   1       1   3 
_6   1          2 
_7 1            1 
1_2014_1             2 
1_2015_1     1        6 
_2 1  1          4 
_3 1           1 2 
2_2014_1           1  1 
_2 1  1          3 
2_2015_1             2 
3_2007_1         1 1   6 
3_2012_1   1      1    3 
3_2013_1        1     1 
_2             1 
3_2014_1     1        3 
_2            1 2 
_3   1          5 
3_2015_1   1 1 1  1      5 
_2        1     1 
4_2006_1   1          3 
4_2013_1    1 1 1 1  1    8 
4_2014_1     1        3 
_2           1  1 
_3 1  1          3 
_4       1     1 2 
_5            1 2 
4_2015_1             4 
_2             2 
_3             3 
_4 1           1 2 
_5   1          2 
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  Representation Tracking 
 Code 13 14 15 16 17 18 19 20 21 22 23 24 ALL 
A
rt
ic
le
 T
ra
ck
in
g
 
_6   1 1         4 
_7            1 2 
_8   1        1  3 
5_2006_1 1 1 1       1   8 
5_2007_1 1 1 1          5 
_2         1 1   8 
_3          1   6 
5_2008_1    1 1    1 1   9 
_2      1   1 1   5 
5_2010_1   1        1  10 
_2 1  1          2 
_3   1 1     1 1   9 
_4     1     1   4 
_5         1    2 
_6    1     1 1   4 
_7         1 1   4 
_8             3 
_9     1     1   5 
_10 1    1 1 1   1   8 
_11   1 1 1        6 
5_2011_1          1   4 
_2    1  1 1  1 1   6 
_3  1   1        3 
5_2012_1 1  1  1        6 
_2 1  1 1      1   8 
_3   1     1  1   4 
_4     1        2 
5_2013_1        1     1 
_2    1 1        4 
_3     1        2 
_4 1    1        4 
_5    1  1 1      4 
_6 1 1   1      1  6 
5_2014_1    1 1  1      5 
_2   1 1 1        5 
_3   1 1 1    1    5 
_4           1  2 
_5     1     1 1 1 7 
5_2015_1   1  1        6 
_2   1  1      1  4 
_3     1        3 
_4     1        4 
_5 1            2 
_6   1        1  3 
_7     1        3 
_8     1        3 
_9        1     3 
_10   1          4 
6_2014_1           1  1 
_2 1  1          3 
6_2015_1   1          2 
_2   1          3 
7_2007_1   1          3 
_2 1            2 
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  Representation Tracking 
 Code 13 14 15 16 17 18 19 20 21 22 23 24 ALL 
A
rt
ic
le
 T
ra
ck
in
g
 
7_2008_1   1 1 1    1 1 1  11 
_2 1  1          4 
_3  1 1  1 1     1  12 
7_2013_1  1 1          4 
_2 1    1        4 
7_2015_1   1          4 
8_2007_1    1     1 1   9 
_2  1 1 1 1  1  1 1 1  13 
8_2008_1         1 1   7 
_2   1  1        8 
8_2009_1    1 1    1    8 
8_2010_1    1 1    1 1   7 
_2      1 1      4 
8_2011_1   1          7 
8_2013_1     1        3 
_2 1    1        5 
_3   1 1 1      1 1 10 
8_2015_1        1     2 
9_2007_1    1     1 1   6 
9_2008_1       1      2 
_2   1          4 
9_2012_1    1 1        2 
9_2014_1             4 
10_2006_1     1        4 
10_2007_1         1 1   6 
_2   1 1 1    1 1   13 
10_2008_1         1 1   5 
10_2009_1   1 1 1  1  1    11 
10_2010_1   1 1 1    1 1   11 
_2    1      1   2 
_3   1 1 1     1   9 
10_2012_1   1 1 1     1   7 
_2        1     3 
_3   1          4 
_4       1 1     3 
10_2013_1 1  1   1    1   5 
_2     1       1 6 
_3 1  1 1 1    1  1 1 14 
10_2014_1   1    1 1 1    4 
_2           1  6 
_3   1          2 
_4   1          2 
_5            1 4 
10_2015_1            1 2 
_2   1  1  1      5 
_3 1    1      1 1 8 
_4   1        1  3 
_5 1  1          2 
_6    1 1 1       5 
_7 1  1   1  1     11 
_8 1  1         1 6 
_9 1  1 1 1 1 1      9 
_10 1    1  1      5 
_11   1 1 1     1   10 
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Figure 8: Occurrence Totals for Each Representation by Year 
 
REPRESENTATION 1 2 3 4 5 6 7 8 9 10 11 12 
ALL 2006 3 1 1 1 0 2 3 1 4 4 2 2 
ALL 2007 6 9 1 5 4 5 2 0 5 5 2 2 
ALL 2008 10 9 1 8 3 5 3 2 8 6 2 1 
ALL 2009 1 1 0 2 1 2 1 0 2 2 0 0 
ALL 2010 9 7 2 5 2 4 2 1 6 8 6 1 
ALL 2011 4 2 0 1 3 4 2 2 1 1 1 1 
ALL 2012 1 5 0 0 1 3 5 3 2 3 1 4 
ALL 2013 1 3 1 2 2 1 6 9 4 7 6 4 
ALL 2014 7 1 2 1 1 1 6 6 2 7 2 2 
ALL 2015 11 4 1 2 7 1 10 12 6 20 6 3 
TOTAL 53 42 9 27 24 28 40 36 40 63 28 20 
 
REPRESENTATION  13 14 15 16 17 18 19 20 21 22 23 24 ALL 
ALL 2006  4 1 3 0 1 1 0 1 0 1 1 0 37 
ALL 2007  2 2 4 4 2 0 1 0 7 8 1 0 77 
ALL 2008  2 2 9 2 6 2 1 0 7 7 3 0 99 
ALL 2009  1 0 1 2 2 0 1 0 3 0 0 0 22 
ALL 2010  2 0 7 7 9 3 2 0 7 12 1 0 103 
ALL 2011  1 1 1 1 1 2 1 0 2 2 0 0 34 
ALL 2012  5 0 7 4 4 0 1 4 2 3 0 0 58 
ALL 2013  8 2 8 7 12 5 3 2 2 2 3 3 103 
ALL 2014  3 0 9 3 6 0 3 1 2 1 6 5 77 
ALL 2015  10 0 19 5 14 3 4 4 0 1 5 6 154 
TOTAL  38 8 68 35 57 16 17 12 32 37 20 14 764 
 
Figure 9: List of Articles Included in Final Data Set Database by Source & Title 
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APPENDIX B. 
Supplemental to CHAPTER TWO 
 
 
Figure 1: Verification gels of pcDNA3.1+ and dCas9 
 
 
 
Lane 1 in both gels contains pcDNA3.1+  
Lane 2 in both gels contains amplified dCas9 
 
 
Figure 2: Visualization Gels for Gradient-temperature Reactions in dCas9 PCR 
Protocol Optimization 
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The temperature range over the 12 reactions was 45 to 62, spanning 17 degrees, each 
reaction representing a difference of 12/17=1.42 degrees. 
 
Reactions 8-11 are the most effective,  
evidenced by the brightest, cleanest, thickest bands. 
 
Therefore, Reaction 9 is 45+(9*1.42)=57.78 degrees.  
Reaction 10 is 45+(10*1.42)=59.2 degrees. 
 
Averaging the temperatures of reactions 9 and 10,  
we can conclude that the optimal temperature for the annealing step in our PCR 
protocol for dCas9 should be 58.49 or 58.5 degrees. 
 
The temperature we were using before performing this optimization was 55 degrees. 
 
 
Figure 3: Verification gel of dCas9 Amplification 
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Figure 4: Vector Map of pcDNA3.1+ Plasmid (Addgene) 
 
 
 
 
Figure 5: Vector Map of BE2 Plasmid Construct (Addgene) 
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Figure 6: Vector Map of pRETRO Plasmid (Addgene) 
 
 
 
 
